PEGBIO CO-B (02565) Schedules 23 Mar 2026 Board Meeting to Approve FY 2025 Results

Bulletin Express

Mar 11

PEG Bio Co., Ltd. (PEGBIO CO-B, stock code 02565) announced that its board of directors will convene on 23 March 2026. The agenda includes reviewing and approving the Group’s audited annual results for the financial year ended 31 December 2025 and authorising their publication. Additional routine matters may also be transacted during the session.

The notice was issued on 11 March 2026 by Chairman, Executive Director, and General Manager Dr. Michael Min XU. The current board composition comprises two executive directors, four non-executive directors, and three independent non-executive directors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1149352945"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149352945\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149352945?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149352945","market":"us","top_or_hot":-1,"title":"PEGBIO CO-B (02565) Schedules 23 Mar 2026 Board Meeting to Approve FY 2025 Results","media":"Bulletin Express","content":"<p>PEG Bio Co., Ltd. (PEGBIO CO-B, stock code 02565) announced that its board of directors will convene on 23 March 2026. The agenda includes reviewing and approving the Group’s audited annual results for the financial year ended 31 December 2025 and authorising their publication. Additional routine matters may also be transacted during the session.</p>\n<p>The notice was issued on 11 March 2026 by Chairman, Executive Director, and General Manager Dr. Michael Min XU. The current board composition comprises two executive directors, four non-executive directors, and three independent non-executive directors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PEGBIO CO-B (02565) Schedules 23 Mar 2026 Board Meeting to Approve FY 2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPEGBIO CO-B (02565) Schedules 23 Mar 2026 Board Meeting to Approve FY 2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-11 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PEG Bio Co., Ltd. (PEGBIO CO-B, stock code 02565) announced that its board of directors will convene on 23 March 2026. The agenda includes reviewing and approving the Group’s audited annual results for the financial year ended 31 December 2025 and authorising their publication. Additional routine matters may also be transacted during the session.</p>\n<p>The notice was issued on 11 March 2026 by Chairman, Executive Director, and General Manager Dr. Michael Min XU. The current board composition comprises two executive directors, four non-executive directors, and three independent non-executive directors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1149352945","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149352945","pubTimestamp":1773218569,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"PEG Bio Co., Ltd. (PEGBIO CO-B, stock code 02565) announced that its board of directors will convene on 23 March 2026. The agenda includes reviewing and approving the Group’s audited annual results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"PEGBIO CO-B(02565)计划于2026年3月23日召开董事会批准2025财年业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PEG Bio Co., Ltd. (PEGBIO CO-B, stock code 02565) announced that its board of directors will convene on 23 March 2026. The agenda includes reviewing and approving the Group’s audited annual results for the financial year ended 31 December 2025 and authorising their publication. Additional routine matters may also be transacted during the session.\nThe notice was issued on 11 March 2026 by Chairman, Executive Director, and General Manager Dr. Michael Min XU. The current board composition comprises two executive directors, four non-executive directors, and three independent non-executive directors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}